Resultados globales: 6 registros encontrados en 0.02 segundos.
Artículos, Encontrados 6 registros
Artículos Encontrados 6 registros  
1.
18 p, 1.4 MB Skin Temperature Circadian Rhythms and Dysautonomia in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome : The Role of Endothelin-1 in the Vascular Tone Dysregulation / Cambras, Trinitat (Universitat de Barcelona) ; Zerón-Rugerio, Maria Fernanda (Universitat de Barcelona) ; Díez-Noguera, Antoni (Universitat de Barcelona) ; Zaragoza, Maria Cleofé (Laboratorios Viñas) ; Domingo, Joan Carles (Universitat de Barcelona) ; Sanmartin Sentañes, Ramon (Hospital Universitari Vall d'Hebron) ; Alegre Martín, José (Hospital Universitari Vall d'Hebron) ; Castro-Marrero, Jesús (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
There is accumulating evidence of autonomic dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS); however, little is known about its association with circadian rhythms and endothelial dysfunction. [...]
2023 - 10.3390/ijms24054835
International journal of molecular sciences, Vol. 24 (march 2023)  
2.
23 p, 3.3 MB Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice / Vergara, Ander (Hospital Universitari Vall d'Hebron) ; Jacobs-Cachá, Conxita (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Llorens-Cebria, Carmen (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ortiz, Alberto (Universidad Autónoma de Madrid) ; Martinez-Diaz, Irene (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Martos, Nerea (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Dominguez-Báez, Pamela (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Van den Bosch, Mireia Molina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Bermejo García, Sheila (Hospital Universitari Vall d'Hebron) ; Pieper, Michael Paul (Boehringer Ingelheim Pharma GmbH (Alemanya)) ; Benito, Begoña (Universitat Autònoma de Barcelona. Departament de Medicina) ; Soler, Maria Jose (Hospital Universitari Vall d'Hebron)
Treatments with sodium-glucose 2 cotransporter inhibitors (SGLT2i) or endothelin receptor antagonists (ERA) have shown cardiorenal protective effects. The present study aimed to evaluate the cardiorenal beneficial effects of the combination of SGLT2i and ERA on top of renin-angiotensin system (RAS) blockade. [...]
2022 - 10.3390/ijms232112823
International journal of molecular sciences, Vol. 23 (october 2022)  
3.
12 p, 7.3 MB Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH / Bravo, Miren (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Raurell, Imma (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Barberá Bellés, Aurora (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Hide, Diana (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Gil, Mar (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Estrella, Federico (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Salcedo, Maria-Teresa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Augustin Recio, Salvador (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Genescà Ferrer, Joan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Martell, María (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
In non-alcoholic steatohepatitis (NASH), decreased nitric oxide and increased endothelin-1 (ET-1, also known as EDN1) released by sinusoidal endothelial cells (LSEC) induce hepatic stellate cell (HSC) contraction and contribute to portal hypertension (PH). [...]
2021 - 10.1242/dmm.048884
Disease Models & Mechanisms, Vol. 14 (may 2021)  
4.
9 p, 975.3 KB Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan : what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? / Fernández-Fernández, Beatriz (GEENDIAB) ; Fernandez-Prado, Raul (GEENDIAB) ; Górriz, Jose Luis (Hospital Clínic Universitari (València)) ; Martínez-Castelao, Alberto (Hospital Universitari de Bellvitge) ; Navarro-González, Juan F. (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife)) ; Porrini, Esteban (Instituto de Tecnologías Biomédicas, Hospital Universitario de Canarias) ; Soler, María José (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ortiz, Alberto (GEENDIAB) ; Universitat Autònoma de Barcelona
In April 2019, two major Phase 3 randomized clinical trials were published that assessed primary renal outcomes in diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM). The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) tested an already available antidiabetic drug, canagliflozin, and the Study of Diabetic Nephropathy with Atrasentan (SONAR) tested a novel molecule, the endothelin-1 receptor blocker atrasentan, both on top of renin-angiotensin system blockade. [...]
2019 - 10.1093/ckj/sfz070
Clinical Kidney Journal, Vol. 12 (may 2019) , p. 313-321  
5.
15 p, 3.4 MB Topical Administration of Bosentan Prevents Retinal Neurodegeneration in Experimental Diabetes / Bogdanov, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Simó-Servat, Olga (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Sampedro, Joel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Solà-Adell, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Garcia-Ramírez, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ramos, Hugo (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Guerrero, Marta (Universitat de Barcelona. Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica) ; Suñé-Negre, Josep Maria (Universitat de Barcelona. Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica) ; Ticó, Josep Ramon (Universitat de Barcelona. Departament de Farmàcia i Tecnologia Farmacèutica, i Fisicoquímica) ; Montoro, Bruno (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Durán, Vicente (Medical Mix S.L.U.) ; Arias Barquet, Lluís (Hospital Universitari de Bellvitge) ; Hernández, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Simó Canonge, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina)
Experimental evidence suggests that endothelin 1 (ET-1) is involved in the development of retinal microvascular abnormalities induced by diabetes. The effects of ET-1 are mediated by endothelin A- and B-receptors (ETA and ETB). [...]
2018 - 10.3390/ijms19113578
International journal of molecular sciences, Vol. 19 Núm. 11 (13 2018)  
6.
11 p, 2.1 MB Transient Mesenteric Ischemia Leads to Remodeling of Rat Mesenteric Resistance Arteries / Caracuel Cano, Laura (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Jiménez Altayó, Francesc (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Romo, Mónica (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Márquez-Martín, Ana (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Dantas, A. P. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Vila Calsina, Elisabet (Universitat Autònoma de Barcelona. Institut de Neurociències)
Mesenteric ischemia/reperfusion (I/R) is associated with high rates of morbidity and mortality. We studied the effect of mesenteric I/R on structural and mechanical properties of rat mesenteric resistance artery (MRA) that, once disrupted, might impact the outcome of this devastating clinical condition. [...]
2012 - 10.3389/fphys.2011.00118
Frontiers in physiology, Vol. 2 (january 2012)  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.